Zhengye Biotechnology (ZYBT) furnishes unaudited six-month 2025 statements

Rhea-AI Filing Summary

Zhengye Biotechnology Holding Limited filed a Form 6-K as a foreign private issuer, furnishing unaudited consolidated financial statements and notes for the six months ended June 30, 2025. The exhibits also include unaudited consolidated financial statements and notes for the six months ended June 30, 2025 and 2024, together with management’s discussion and analysis of financial condition and results of operations for the same interim period. Related Inline XBRL instance and taxonomy extension files are provided to present the financial data in structured electronic format.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 12/12/2025 - 04:10 PM Learn about SEC filing dates

FAQ

What did Zhengye Biotechnology Holding Limited (ZYBT) disclose in this Form 6-K?

Zhengye Biotechnology Holding Limited furnished unaudited consolidated financial statements and notes for the six months ended June 30, 2025, along with a management’s discussion and analysis of financial condition and results of operations for the same period as exhibits to the Form 6-K.

Which periods are covered by Zhengye Biotechnology’s unaudited financial statements in this filing?

The unaudited consolidated financial statements and notes of Zhengye Biotechnology Holding Limited cover the six months ended June 30, 2025 and 2024, as described in Exhibit 99.1.

What additional analysis accompanies Zhengye Biotechnology’s interim financial statements?

The filing includes an exhibit containing Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025, providing narrative discussion to accompany the interim financial statements.

In what electronic format are Zhengye Biotechnology’s financial data files provided?

The financial information is accompanied by Inline XBRL files, including an Inline XBRL instance document and related taxonomy extension schema, calculation, definition, label, and presentation linkbase documents.

Who signed Zhengye Biotechnology’s December 2025 Form 6-K?

The Form 6-K was signed on behalf of Zhengye Biotechnology Holding Limited by Songlin Song, who is identified as the company’s Chief Executive Officer, dated December 12, 2025.

Does Zhengye Biotechnology file its annual reports on Form 20-F or Form 40-F?

The company indicates that it files annual reports under cover of Form 20-F, consistent with its status as a foreign private issuer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-42450

Zhengye Biotechnology Holding Limited

No.1 Lianmeng Road, Jilin Economic & Technical Development Zone

Jilin City, Jilin Province, China
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒        Form 40-F ☐

Explanatory Note

Zhengye Biotechnology Holding Limited, a Cayman Islands exempted company (the “Company”), is furnishing its unaudited financial statements and notes for the six months ended June 30, 2025. The financial statements and notes are attached as Exhibit 99.1 to this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025 is attached as Exhibit 99.2 to this report.

Exhibit Index

Exhibit No.		Description
99.1		Unaudited Consolidated Financial Statements and Notes of Zhengye Biotechnology Holding Limited for the Six Months Ended June 30, 2025 and 2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations
101. INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Zhengye Biotechnology Holding Limited
Date: December 12, 2025	By:	/s/ Songlin Song
	Name:	Songlin Song
	Title:	Chief Executive Officer

2